Home > Disclaimer > Late Effects


Late Effects

Second Malignant Neoplasm




National Cancer Institute: Second Malignant Neoplasms

Medical radiation exposure at the National Cancer Institute



Second cancers caused by cancer treatment (American Cancer Society)

Livestrong: Second Cancers

From Children's Oncology Group Survivorship Guidelines:

Breast cancer following treatment for childhood cancer: Are you at risk?

Reducing the risk of second cancers

Colorectal cancer following treatment for childhood cancer



1. Peterson KM, Shao C, McCarter R, et al: An analysis of SEER data of increasing risk of secondary malignant neoplasms among long-term survivors of childhood brain tumors. Pediatr Blood Cancer 47:83-88, 2006

2. Garwicz S, Anderson H, Olsen JH, et al: Second malignant neoplasms after cancer in childhood and adolescence: A population-based case-control study in the 5 nordic countries. the nordic society for pediatric hematology and oncology. the association of the nordic cancer registries. Int J Cancer 88:672-678, 2000

3. Robison LL: Treatment-associated subsequent neoplasms among long-term survivors of childhood cancer: The experience of the childhood cancer survivor study. Pediatr Radiol 39 Suppl 1:S32-7, 2009

4. Woo KI, Harbour JW: Review of 676 second primary tumors in patients with retinoblastoma: Association between age at onset and tumor type. Arch Ophthalmol 128:865-870, 2010

5. Godley LA, Larson RA: Therapy-related myeloid leukemia. Semin Oncol 35:418-429, 2008

6. Shimura K, Shimazaki C, Okano A, et al: [Therapy-related myeloid leukemia following platinum-based chemotherapy for ovarian cancer]. Rinsho Ketsueki - Japanese Journal of Clinical Hematology 42:99-103, 2001

7. Felix CA: Leukemias related to treatment with DNA topoisomerase II inhibitors. Med Pediatr Oncol 36:525-535, 2001

8. Pedersen-Bjergaard J, Philip P: Balanced translocations involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II. Blood 78:1147-1148, 1991

9. Schonfeld SJ, Gilbert ES, Dores GM, et al: Acute myeloid leukemia following hodgkin lymphoma: A population-based study of 35,511 patients. J Natl Cancer Inst 98:215-218, 2006

10. Hijiya N, Ness KK, Ribeiro RC, et al: Acute leukemia as a secondary malignancy in children and adolescents: Current findings and issues. Cancer 115:23-35, 2009

11. Greenfield DM, Wright J, Brown JE, et al: High incidence of late effects found in hodgkin's lymphoma survivors, following recall for breast cancer screening. Br J Cancer 94:469-472, 2006

12. Green DM, Hyland A, Barcos MP, et al: Second malignant neoplasms after treatment for hodgkin's disease in childhood or adolescence. Journal of Clinical Oncology 18:1492-1499, 2000

13. Travis LB, Hill D, Dores GM, et al: Cumulative absolute breast cancer risk for young women treated for hodgkin lymphoma. J Natl Cancer Inst 97:1428-1437, 2005

14. Saslow D, Boetes C, Burke W, et al: American cancer society guidelines for breast screening with MRI as an adjunct to mammography. CA: a Cancer Journal for Clinicians 57:75-89, 2007

15. Oeffinger KC, Ford JS, Moskowitz CS, et al: Breast cancer surveillance practices among women previously treated with chest radiation for a childhood cancer. JAMA 301:404-414, 2009

16. Ng AK, Bernardo MVP, Weller E, et al: Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: Long-term risks and risk factors. Blood 100:1989-1996, 2002



Back to top